Last reviewed · How we verify

Previscan (FLUINDIONE)

Phase 2 active Small molecule Quality 41/100

Previscan (generic name: FLUINDIONE) is a fluindione drug. It is currently in Phase 2 development.

Previscan works by inhibiting vitamin K-dependent clotting factors in the liver.

Previscan (FLUINDIONE) is a small molecule drug in the fluindione class, but specific details about its target and mechanism of action are not available. It is not clear if it is FDA-approved or off-patent. The approved indications for Previscan are not specified. As a result, its commercial status, half-life, bioavailability, and generic manufacturers are also unknown. Further research is needed to understand the safety considerations and clinical use of Previscan.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameFLUINDIONE
Drug classfluindione
TargetArachidonate 5-lipoxygenase
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 2

Mechanism of action

Think of it like a brake on your car's engine. Previscan blocks a specific part of the engine that helps make blood clots, which can prevent strokes and heart attacks. By blocking this part, Previscan helps prevent blood clots from forming.

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Previscan

What is Previscan?

Previscan (FLUINDIONE) is a fluindione drug.

How does Previscan work?

Previscan works by inhibiting vitamin K-dependent clotting factors in the liver.

What is the generic name of Previscan?

FLUINDIONE is the generic (nonproprietary) name of Previscan.

What drug class is Previscan in?

Previscan belongs to the fluindione class. See all fluindione drugs at /class/fluindione.

What development phase is Previscan in?

Previscan is in Phase 2.

What are the side effects of Previscan?

Common side effects of Previscan include Atrial fibrillation, Pyrexia, Atrial flutter, Dyspnea, Palpitations, Nasopharyngitis.

What does Previscan target?

Previscan targets Arachidonate 5-lipoxygenase and is a fluindione.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing